Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. announced that their cancer treatment drug, HANSIZHUANG, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, signaling a step closer to approval for use in the EU. The drug, intended for first-line treatment of extensive-stage small cell lung cancer in combination with chemotherapy, has shown significant benefits in clinical trials. If approved by the European Commission, HANSIZHUANG will be authorized for marketing across EU Member States and additional European countries.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.